Insilico nominates ISM1354 GIPR drug candidate with 18-fold exposure advantage
AI Summary- Insilico Medicine nominated ISM1354, an AI-driven GIPR antagonist candidate for obesity-related disorders.
- ISM1354 achieved 75% to 104% oral bioavailability and at least 18-fold higher plasma exposure.
- Insilico nominated 10 preclinical candidates during the first nine months of 2026.